

Institutional Biosafety Committee Meeting

4/9/2026

10:30am-12:00pm

Zoom Virtual Meeting

Institutional Biosafety Committee Meeting minutes

Meeting Attendance:

- Members in attendance:
 - Elena Demireva
 - Jonathan Hardy
 - Sarah Roosa
 - Jamie Willard-Smith
 - Dave Morgan
 - Carolina de Aguiar Ferreira
 - Raj Kulkarni
 - Michael Bachmann
 - Guo-Qing Song
 - Carrie Anglewicz

- Members not in attendance:
 - Jan Patterson Samson
 - Andras Komaromy

- Others in attendance:
 - Chris Colvin
 - Alessandra Hunt
 - Luis Ochoa Carrera

Call to order:

Sarah Roosa

Roll call:

Chris Colvin

Discussion of the agenda:

- Approved

Discussion of minutes:

- Approved

Institutional Biosafety Committee Meeting

4/9/2026

10:30am-12:00pm

Zoom Virtual Meeting

Registration review:

Study Info

Safety0001263: Amend0001683: [REDACTED]

Bartonella from Wild Gerbils

Training: Complete for all members listed

NIH III D-1-a, RG-2, BSL-2

This registration has been approved with edits. The PI has been asked to clarify the following:

- Bacteria
 - 1: If using E. coli for cloning include in the table.
- rDNA Usage
 - 3b: Change Streptomyces pyogenes to Streptococcus pyogenes.
 - 3c: Chloramphenicol is used for treatment in humans.
 - 4b: Include suicide vectors as well as others used.
 - 5a: Include E. coli if used for cloning. Move Bartonella to the recipients section on the rDNA Work Description page question 2. If the Bartonella spp. are used for propagation leave here.
- rDNA Work Description
 - 1: Yes, include purchased vectors and plasmids.
 - 2: If transferring materials back to UT or elsewhere change to yes.
- Exposure Assessment
 - 1: Address possible risks of release to animals as this can colonize mice.
- Waste Management
 - Include Chemical treatment prior to sewer if treating culture waste with bleach and then to sewer.
- Supporting Documents
 - Update the TBD missing information in the handbook.
 - Need a specific SOP for handling and disposal of the Bartonella sp.

Study Info

Safety0001189: [REDACTED]

Plant natural products

Training: Complete for all members listed

NIH III-E-2-a, RG-1, BSL-1

This registration has been approved with edits. The PI has been asked to clarify the following:

- Biosafety Summary
 - 1: Add species for all plants listed.
- rDNA Usage
 - 3b: Add all biological sources for the inserts.
 - 5a: Include the Yeast species

Institutional Biosafety Committee Meeting

4/9/2026

10:30am-12:00pm

Zoom Virtual Meeting

- 5d: Include Tomato and Nicotiana if introducing rDNA into them.
- rDNA Work Description
 - 2: Remove Agrobacteria as it is a host. Remove Yeast if only a host.
- Biosafety Additional Information
 - 1: Update permit information if it has been renewed, if no longer needed this can be changed to No.
 - 3: If you are shipping materials out change to Yes.

Study Info

Safety0001452: [REDACTED]
Evaluation of small RNA Activity and Delivery

Training: Complete for all members listed

NIH III E-1, RG-1, BSL-2

This registration has been approved with edits. The PI has been asked to clarify the following:

- Cells
 - 1: Update all human cell lines to BSL-2.
 - 5: Update A, B, C
 - 5c: Add NCI-H1299
 - 5e. Flow addendum – last table column for testing choose ‘No’ rather than not-applicable as the lines could indeed be tested
- rDNA Work Description
 - 1: Change to Yes and include purchased plasmids and vectors.
- Exposure Assessment
 - 1: Remove statement starting with “None of them present any significant danger” and address the potential risks to Blood Borne Pathogens with the use of human materials.
 - 4: What are the scalpels used for?
- Risk Assessment
 - 1: Update to RG-2 for the use of the HepG2 cell line.
- Supporting Documents
 - Safer sharps document: There are alternatives for glass pipettes, remove statement that says there are no alternatives.

Study Info

Safety0001463: [REDACTED]
Waters chemical signaling and phages

Training: Complete for all members listed

NIH III D-2-a, RG-2, BSL-2

Institutional Biosafety Committee Meeting

4/9/2026

10:30am-12:00pm

Zoom Virtual Meeting

This registration has been approved with edits. The PI has been asked to clarify the following:

- Biosafety Summary
 - 2: Add more information to clarify the work with Vibrio El-Tor strain as this strain does not produce the toxin without subculturing or extra steps.
 - 2: Include your infectious dose of Vibrio used. It is stated elsewhere that it is 3ml of 2×10^9 .
- Bacteria
 - 1: Update Vibrio, change “used in animals” to no.
 - 2: Remove strain or add to the rest of the registration.
 - 3e: Update addendum, in second column add the transfection method used. Add E. coli to addendum.
- Virus
 - 2: Remove information as this is stated in the activities in the table.
- rDNA Usage
 - 3b: Include source and species for all inserts. Include RFP.
 - 7: Change to No if just using for selection.
- Exposure Assessment
 - 1: Include the symptoms for Psuedomonas and update to the correct infectious dose used.
 - Remove statement on lab acquired infections.
 - 3: Update eyewash date
- Supporting Documents
 - Update BMBL to the 6th edition.

Study Info

Safety0001471: XXXXXXXXXX

Synthetic Prokaryotic Endosymbionts-3

Training: Complete for all members listed

NIH III D-4-c, RG-2, BSL-2+

This registration has been approved with edits. The PI has been asked to clarify the following:

- Biosafety Summary
 - 2: Include information for the use of Lentivirus, Magnetospirillum and MMLV. Include how and why it is being used.
 - 2: Why is KRAS being expressed with Lentivirus? Justify this method.
- Cells
 - 1: Include CIK cells.
- Virus
 - 1: Clarify if using 2nd generation lentivirus or just 3rd generation. 2nd generation virus is included the rDNA section.
- rDNA Usage

Institutional Biosafety Committee Meeting

4/9/2026

10:30am-12:00pm

Zoom Virtual Meeting

- 4b: Include vectors described elsewhere in the document including the flow core addendum.
- 5a: Remove all except for E. coli as they are recipients.
- 9: Fix typo “with water thoroughly with water”.
- rDNA Work Description
 - 5: If using 2nd generation leave here but need to include in the Virus section that 2nd generation is being used.
 - The IBC recommends switching from a 2nd generation Lentivirus to a 3rd or later generation for increased safety features.
- Exposure Assessment
 - 1: Address the risks of Blood Borne Pathogens with the use of human cell lines.
- Supporting Documents
 - Add Scalpels to sharps forms.

New Items:

- Team member page has been updated to include the proper training records for members that are listed.

Previous Submissions:

- Safety0001211 ■

Next Meeting:

- May 6, 2026, 1:30 pm via zoom